Q-omics provides the consensus-scored PIFO profile across patient tissues and cancer cell-line models. PIFO expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PIFO is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PIFO RNA expression shows 17,263 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where PIFO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIFO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIFO survival associations across molecular data types. PIFO RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIFO RNA expression–survival associations across cancer types. High PIFO expression shows unfavorable associations in SCLC and LGG, but favorable associations in ACC, KIRC, KIRP and UVM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PIFO RNA expression.
This table summarizes PIFO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PIFO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIFO shows lower tumor expression in KICH, LUAD, LUSC, BLCA, THCA and HNSC. The KICH box plot shows higher PIFO RNA expression in normal versus tumor tissue (log2 FC = −2.568, t-test p < 0.001).
This table shows molecular features associated with PIFO in patient tissues and cancer cell lines. In patient samples, PIFO shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PIFO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
